# LivaNova completes initial closing of heart valve business sale to Gyrus Capital

LivaNova completed the initial closing of the divestiture of its heart valve business to Gyrus Capital for €60 million ($73 million). The business will be managed by Corcym, which acquired the Saluggia and Vancouver manufacturing facilities.

- Type: Acquisition
- Announced: 2021-06-01
- Where: Saluggia and Vancouver
- Value: $73.0M (60.0M EUR)
- Status: completed
- Products: Perceval sutureless aortic valve, Memo 4D mitral annuloplasty ring, mechanical valves
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [LivaNova](https://endata.com/companies/8038.md) (partner)
- [Gyrus Capital](https://endata.com/companies/8039.md) (acquirer)
- [Corcym](https://endata.com/companies/8040.md) (acquirer)

## Sources

- [dicardiology.com](https://www.dicardiology.com/content/livanova-sells-heart-valve-business-gyrus-capital), 2021-06-02: "LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart valve business to the investment firm Gyrus Capital for €60 million ($73 million)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.